Follow-On Offering

Healthcare
Follow-On Offering

Summary

Baird served as co-manager on this transaction.

About

Curis, Inc. (“Curis” or the “Company”) (NASDAQ-GS: CRIS) recently completed a follow-on offering of approximately 28,000,000 shares of common stock at a price of $2.75 per share, generating gross proceeds of approximately $65 million. The Company intends to use the net proceeds from the offering to conduct further preclinical testing and clinical studies of its product candidates, particularly CUDC-907 and any product candidates for which it exercises its option to exclusively in-license from Aurigene, to fund potential acquisitions of new business, technologies or products that it believes complements or expands the business, and for general working capital and capital expenditures.

Curis is an oncology-focused biotechnology company developing novel candidates for the treatment of human cancers. The Company’s proprietary pipeline includes two clinical stage drug candidates: CUDC-907, a dual HDAC and P13K inhibitor, and CUDC-427, a small molecule IAP antagonist. The Company is headquartered in Lexington, Massachusetts.

For additional information about this transaction, please contact:

David Schechner +1 (617) 426-5424
Lance Lange +1 (414) 765-7079
Satoshi Matsumoto +1 (312) 609-5446
Vipul Patel +1 (312) 609-4933
Brian Thomas +1 (415) 627-3275
Healthcare
Follow-On Offering
Date
February 2015
Company
Curis, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share